CN106916211A - Macc1基因的多肽抑制剂及应用 - Google Patents
Macc1基因的多肽抑制剂及应用 Download PDFInfo
- Publication number
- CN106916211A CN106916211A CN201710268903.1A CN201710268903A CN106916211A CN 106916211 A CN106916211 A CN 106916211A CN 201710268903 A CN201710268903 A CN 201710268903A CN 106916211 A CN106916211 A CN 106916211A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- macc1
- genes
- peptide inhibitor
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 111
- 101001055106 Homo sapiens Metastasis-associated in colon cancer protein 1 Proteins 0.000 title claims abstract description 33
- 239000003112 inhibitor Substances 0.000 title claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 claims abstract description 88
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 88
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 18
- 230000009545 invasion Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 4
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 230000021736 acetylation Effects 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 18
- 238000013518 transcription Methods 0.000 abstract description 2
- 230000035897 transcription Effects 0.000 abstract description 2
- 238000013519 translation Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 42
- 102100026892 Metastasis-associated in colon cancer protein 1 Human genes 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 206010013457 Dissociation Diseases 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 101150009427 MACC1 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 208000018459 dissociative disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- -1 Tetramethyl azo azoles salt Chemical class 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
4μM | 8μM | 16μM | 32μM | 64μM | |
多肽Ⅱ-1组 | 15.34 | 26.22 | 38.84 | 53.65 | 64.47 |
多肽Ⅱ-2组 | 17.62 | 25.94 | 35.49 | 57.26 | 65.83 |
多肽Ⅱ-3组 | 13.58 | 24.63 | 36.48 | 55.54 | 68.42 |
多肽Ⅱ-4组 | 15.07 | 25.32 | 37.26 | 56.08 | 66.16 |
4μM | 8μM | 16μM | 32μM | 64μM | |
多肽Ⅱ-1组 | 88.78 | 76.75 | 53.36 | 38.32 | 23.05 |
多肽Ⅱ-2组 | 89.54 | 77.48 | 50.48 | 37.18 | 24.69 |
多肽Ⅱ-3组 | 91.36 | 79.32 | 54.29 | 39.04 | 23.84 |
多肽Ⅱ-4组 | 87.49 | 80.04 | 55.88 | 36.44 | 25.07 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710268903.1A CN106916211B (zh) | 2017-04-24 | 2017-04-24 | Macc1基因的多肽抑制剂及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710268903.1A CN106916211B (zh) | 2017-04-24 | 2017-04-24 | Macc1基因的多肽抑制剂及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106916211A true CN106916211A (zh) | 2017-07-04 |
CN106916211B CN106916211B (zh) | 2020-09-29 |
Family
ID=59568000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710268903.1A Active CN106916211B (zh) | 2017-04-24 | 2017-04-24 | Macc1基因的多肽抑制剂及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106916211B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641653A (zh) * | 2017-10-20 | 2018-01-30 | 南方医科大学南方医院 | Macc1‑as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725398A (zh) * | 2015-01-29 | 2015-06-24 | 杨威 | 一种jak/stat3磷酸化抑制剂及其制备方法与用途 |
WO2016020427A1 (en) * | 2014-08-05 | 2016-02-11 | Charité - Universitätsmedizin Berlin | Macc1 inhibitors and use thereof in the treatment of cancer |
-
2017
- 2017-04-24 CN CN201710268903.1A patent/CN106916211B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016020427A1 (en) * | 2014-08-05 | 2016-02-11 | Charité - Universitätsmedizin Berlin | Macc1 inhibitors and use thereof in the treatment of cancer |
CN104725398A (zh) * | 2015-01-29 | 2015-06-24 | 杨威 | 一种jak/stat3磷酸化抑制剂及其制备方法与用途 |
Non-Patent Citations (3)
Title |
---|
LI HF ET AL.: "Downregulation of MACC1 inhibits invasion, migration and proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell carcinoma", 《ONCOL REP.》 * |
张秀梅等: "肝细胞癌中MACC1基因的表达及其临床意义 ", 《长江大学学报(自科版)》 * |
张秀梅等: "肝细胞癌中MACC1基因的表达及其临床意义", 《长江大学学报(自科版)》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641653A (zh) * | 2017-10-20 | 2018-01-30 | 南方医科大学南方医院 | Macc1‑as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用 |
CN107641653B (zh) * | 2017-10-20 | 2021-02-19 | 南方医科大学南方医院 | Macc1-as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106916211B (zh) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fang et al. | Actinidia chinensis Planch root extract attenuates proliferation and metastasis of hepatocellular carcinoma by inhibiting epithelial-mesenchymal transition | |
EP3040072A1 (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
Liu et al. | Pro-inflammatory cytokine-driven PI3K/Akt/Sp1 signalling and H2S production facilitates the pathogenesis of severe acute pancreatitis | |
Kim et al. | A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo | |
WO2020045547A1 (ja) | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 | |
Zhou et al. | USP4 deficiency exacerbates hepatic ischaemia/reperfusion injury via TAK1 signalling | |
Lee et al. | Matairesinol inhibits angiogenesis via suppression of mitochondrial reactive oxygen species | |
CN113788882B (zh) | 一种枯草芽孢杆菌amep412蛋白在抑制肿瘤细胞增殖中的应用 | |
CN106916211A (zh) | Macc1基因的多肽抑制剂及应用 | |
CN107474115A (zh) | 一种多肽及其在制备治疗和/或预防肿瘤的药物中的应用 | |
WO2019091013A1 (zh) | 一种no供体化合物在制备抑制富含巯基分子的肿瘤细胞的侵袭和转移能力药物中的应用 | |
CN107082800A (zh) | 一种macc1基因的抑制剂及其抗肝细胞癌侵袭用途 | |
CN108553455B (zh) | 三醛基间苯三酚缩氨基硫脲杂合体化合物在抗肿瘤药物中的应用 | |
CN108938638A (zh) | Zinc62678696在制备抑制肝纤维化药物的用途 | |
Zhu et al. | HIF‐1α RNAi Combined with Asparagus Polysaccharide Exerts an Antiangiogenesis Effect on Hepatocellular Carcinoma In Vitro and In Vivo | |
CN113461675B (zh) | 一种针对skp2的小分子抑制剂tak-491及其应用 | |
CN111419865B (zh) | 一种双裂孕烷型甾体化合物在制备抗红白血病药物中的应用 | |
CN112410429A (zh) | Fxyd3作为胃癌诊断标志物和治疗靶标的应用 | |
CN114164176A (zh) | 人膀胱癌顺铂耐药细胞株及其用途 | |
CN109321578A (zh) | Foxm1基因、用于检测其的试剂盒及其用途 | |
CN114452280B (zh) | 苍术酮在制备胶质瘤治疗药物中的应用 | |
CN108660208B (zh) | 一种检测奥沙利铂对于肝癌化疗敏感性的试剂盒及其应用 | |
Wang et al. | Significance and Expression of Atypical Protein Kinase C-ɩ in Human Hepatocellular Carcinoma | |
Ma et al. | lncRNA LINC00152 knockdown suppressed hepatic cancer biological activity | |
CN116212053B (zh) | Eaat1/slc1a3抑制剂在制备治疗肝癌药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200902 Address after: Room 801, 238 JIANGCHANG 3rd road, Jing'an District, Shanghai 200040 Applicant after: SHANGHAI TAOSHU BIOTECHNOLOGY Co.,Ltd. Address before: 211198 No. 18 Zhilan Road, Science Park, Jiangning District, Nanjing City, Jiangsu Province Applicant before: NANJING GAISIFU MEDICAL TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Polypeptide Inhibitor of MACC1 Gene and Its Application Effective date of registration: 20220901 Granted publication date: 20200929 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2022310000227 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231122 Granted publication date: 20200929 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2022310000227 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Peptide inhibitors of MACC1 gene and their applications Effective date of registration: 20231221 Granted publication date: 20200929 Pledgee: Bank of Communications Co.,Ltd. Shanghai Jing'an Sub branch Pledgor: SHANGHAI TAOSHU BIOTECHNOLOGY CO.,LTD. Registration number: Y2023310000902 |